Developing Novel Therapeutic Approaches to Frailty

被引：112

作者：

Morley, John E. ^{[1
,2
]}

机构：

[1] St Louis Univ, Sch Med, Div Geriatr Med, St Louis, MO 63104 USA

[2] VA Med Ctr, GRECC, St Louis, MO USA

来源：

CURRENT PHARMACEUTICAL DESIGN | 2009年 / 15卷 / 29期

关键词：

LONG-TERM-CARE; CHRONIC HEART-FAILURE; POLYUNSATURATED FATTY-ACIDS; VITAMIN-D SUPPLEMENTATION; GROWTH-HORMONE SECRETAGOGUE; PROTEIN-ENERGY MALNUTRITION; ALPHA-LIPOIC ACID; LEAN BODY-MASS; WEIGHT-LOSS; OLDER PERSONS;

D O I：

10.2174/138161209789105045

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Frailty is now defined as a clinical entity and potentially responsive to medications. This article reviews the drugs available and those under development. While, at present, exercise is the primary therapy, it is expected over the next decade that numerous drugs will be available to treat components of the frailty syndrome.

引用

页码：3384 / 3395

页数：12

共 181 条

[1]

Abbatecola AM, 2008, CURR PHARM DESIGN, V14, P405

[2]

Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study [J].